TARX (Tarsier Pharma) PB Ratio: (As of Jul. 11, 2026)


What is Tarsier Pharma PB Ratio?

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-11), Tarsier Pharma's share price is $0.00. Tarsier Pharma's Book Value per Share for the quarter that ended in Dec. 2025 was $-0.17. Hence, Tarsier Pharma's PB Ratio of today is .

The historical rank and industry rank for Tarsier Pharma's PB Ratio or its related term are showing as below:

TARX's PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 2.95
* Ranked among companies with meaningful PB Ratio only.

Back to Basics: PB Ratio


Tarsier Pharma  (NYSE:TARX) PB Ratio Explanation

Unlike valuation ratios relative to the earning power such as PE Ratio, PE Ratio without NRI, PS Ratio, Price-to-Operating-Cash-Flow , or Price-to-Free-Cash-Flow, the PB Ratio measures the valuation of the stock relative to the underlying asset of the company.

The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.


Be Aware

Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.


Tarsier Pharma PB Ratio Related Terms


Tarsier Pharma PB Ratio Historical Data

* Premium members only.

The historical data trend for Tarsier Pharma's PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Tarsier Pharma PB Ratio Chart

Tarsier Pharma Annual Data
Trend Dec23 Dec24 Dec25
PB Ratio
0.00 0.00 0.00

Tarsier Pharma Semi-Annual Data
Dec23 Jun24 Dec24 Jun25 Dec25
PB Ratio 0.00 0.00 0.00 0.00 0.00

TARX vs : PB Ratio Comparison

For the Biotechnology subindustry, Tarsier Pharma's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Tarsier Pharma PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Tarsier Pharma's PB Ratio distribution charts can be found below:

* The bar in red indicates where Tarsier Pharma's PB Ratio falls into.



Tarsier Pharma PB Ratio Calculation

The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.

Tarsier Pharma's PB Ratio for today is calculated as follows:

PB Ratio=Share Price/Book Value per Share (Q: Dec. 2025)
=0.00/-0.174
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.


Tarsier Pharma Business Description

Comparable Companies
Tarsier Pharma Ltd is a late clinical stage biopharmaceutical company, focused on the development and commercialization of novel pharmaceutical therapies to address unmet needs in ocular diseases with underlying inflammatory pathologies. Its dazdotuftide platform technology is a bio-inspired immunomodulator designed to treat blinding inflammatory ocular diseases, and is currently being developed as both eye drops and intravitreal injections. The company's Product Candidate Pipeline includes TRS01 and TRS02.